Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.67 |
| ▸ | MC5R | P33032 | 2/20 | 0.67 |
| ▸ | MC3R | P41968 | 2/20 | 0.67 |
| ▸ | MC1R | Q01726 | 2/20 | 0.67 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.64 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.63 |
| ▸ | CXCL8 | P10145 | 6/20 | 0.63 |
| ▸ | CTSL | P07711 | 2/20 | 0.61 |
| ▸ | CTSS | P25774 | 2/20 | 0.61 |
| ▸ | CTSK | P43235 | 2/20 | 0.61 |
| ▸ | CTSH | P09668 | 1/20 | 0.61 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | NPY4R | P50391 | 1/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.60 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462886 | 0.93 | MC4R (0.68) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL30495708 | 0.90 | CXCR4 (0.71) | CXCR4CXCL8NPY1RNPY2RNPY4R | |
| SCHEMBL29361885 | 0.90 | GLP1R (0.66) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL29397826 | 0.88 | CXCL8 (0.64) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL31332244 | 0.88 | CXCL8 (0.64) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL31694497 | 0.88 | CXCR4 (0.64) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL31182648 | 0.87 | NPY2R (0.72) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL30495798 | 0.86 | NPY1R (0.68) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL30186432 | 0.86 | MC4R (0.63) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL29874649 | 0.86 | MC4R (0.69) | MC4RMC5RMC3RMC1RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218926-A2 | COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE | Okyo Pharma Limited (GG) | 2023-08-02 | — | — | EP | claimed |
| US-20220281915-A1 | COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE | OKYO PHARMA LIMITED (GG) | 2022-09-08 | — | — | US | claimed |
| EP-3373947-B1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TUFTS COLLEGE (US) | 2022-03-02 | — | — | EP | claimed |
| US-20260137723-A1 | DEPRIVATION OF HUMAN PLURIPOTENT STEM CELL-DERIVED TRPV1+, MRGPRX1+ AND SCN9A+ SENSORY NEURONS AND THEIR FUNCTIONAL CHARACTERIZATION | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4629974-A1 | NOOTKATONE FOR THE TREATMENT OF GUT OR ABDOMINAL PAIN | Enveda Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4629968-A1 | NOOTKATONE FOR THE TREATMENT OF PRURITUS | Enveda Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250277042-A1 | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF | EBLA HOLDCO, INC. | 2025-09-04 | — | — | US | disclosed |
| CN-120154608-A | Application of traditional Chinese medicine compound as targeting itch receptor MRGPRX and MRGPRX2 antagonist | 山东大学 | 2025-06-17 | — | — | CN | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| WO-2025106999-A1 | DEPRIVATION OF HUMAN PLURIPOTENT STEM CELL-DERIVED TRPV1+, MRGPRX1+ AND SCN9A+ SENSORY NEURONS AND THEIR FUNCTIONAL CHARACTERIZATION | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250002461-A1 | DEUTERATED (TRIFLUOROMETHYL)PYRIMIDINE-2-AMINE COMPOUNDS AS POTENTIATORS OF THE HMRGX1 RECEPTOR | ELI LILLY AND COMPANY | 2025-01-02 | — | — | US | disclosed |
| US-11414389-B2 | (trifluoromethyl)pyrimidine-2-amine compounds | ELI LILLY AND COMPANY (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220195481-A1 | MITOCHONDRIAL RESPIROMETRY IN FROZEN SPECIMENS | THE REGENTS OF THE UNIVERSITY OF CALIFORMIA (US) | 2022-06-23 | — | — | US | disclosed |
| CN-114601912-A | Itch-caused polypeptide caused by tick and mosquito bites and itch-resisting application thereof | 武汉大学 | 2022-06-10 | — | — | CN | disclosed |
| WO-2022119823-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-4007636-A1 | COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE | Okyo Pharma Limited (GG) | 2022-06-08 | — | — | EP | disclosed |
| EP-4007636-A1 | COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE | Okyo Pharma Limited (GG) | 2022-06-08 | — | — | EP | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| EP-3373947-B1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TUFTS COLLEGE (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281915-A1 | COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE | CXCL8, CCR8, IL18 | MC4R 512/4885MC5R 531/4885MC3R 318/4885 |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | MC4R 3238/4885MC5R 3817/4885MC3R 2546/4885 |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | MC4R 4101/4885MC5R 4474/4885MC3R 4210/4885 |
| US-11414389-B2 | (trifluoromethyl)pyrimidine-2-amine compounds | P2RX1, P2RX2, P2RY1 | MC4R 217/4885MC5R 291/4885MC3R 759/4885 |
| US-20260137723-A1 | DEPRIVATION OF HUMAN PLURIPOTENT STEM CELL-DERIVED TRPV1+, MRGPRX1+ AND SCN9A+ SENSORY NEURONS AND THEIR FUNCTIONAL CHARACTERIZATION | TRPV1, MRGPRX1, TRPM4 | MC4R 208/4885MC5R 427/4885MC3R 227/4885 |
| US-20250002461-A1 | DEUTERATED (TRIFLUOROMETHYL)PYRIMIDINE-2-AMINE COMPOUNDS AS POTENTIATORS OF THE HMRGX1 RECEPTOR | P2RX1, P2RX2, P2RX3 | MC4R 119/4885MC5R 71/4885MC3R 79/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | MC4R 3238/4885MC5R 3817/4885MC3R 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.